Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study-Reference-Cited by-同舟云学术

Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study

Published:2018-02-15 Issue:5 Volume:58 Page:1143-1148
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Marchesi Francesco¹^ORCID,Vacca Michele²,Giannarelli Diana³,Ipsevich Francesco²,Pandolfi Annino²,Gumenyuk Svitlana¹,Renzi Daniela¹,Palombi Francesca¹,Pisani Francesco¹,Romano Atelda¹,Spadea Antonio¹,Papa Elena¹,Canfora Marco³,Pierelli Luca²,Mengarelli Andrea¹

Affiliation:

1. Hematology and Stem Cell Transplant Unit

2. Immuno-Transfusional Medicine, Leukapheresis and Cellular Therapy Unit; S. Camillo-Forlanini Hospital; Rome Italy

3. Biostatistics Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute; Regina Elena National Cancer Institute

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.14533/fullpdf

Reference20 articles.

1. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation;Duong;Biol Blood Marrow Transpl,2014